Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SYS6017 Zoster mRNA Vaccine in Healthy Adults
NCT06954818Phase 1Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
01
Overview
Phase 1, randomised, double-blind trial of SYS6017 in herpes zoster (HZ) (6 arms), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd. Primary endpoints: Solicited Adverse Events and Unsolicited Adverse Events. Planned start May 2025; status: not yet recruiting.
02
Drugs
SYS6017
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06954818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954818.